Pasireotide

FDA approved

Pasireotide (Signifor) is a somatostatin analog approved by the FDA in 2012 for Cushing's disease when surgery is not an option, with a long-acting form (Signifor LAR) for acromegaly.

At a glance

Where it acts: Hormones & metabolism
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Pasireotide binds four of the five somatostatin receptor subtypes, with especially high affinity for subtype 5, which is abundant on the pituitary tumors that cause Cushing's disease. This suppresses ACTH and therefore cortisol, as well as growth hormone.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

High blood sugar (very common), diarrhea, nausea, gallstones, headache and abdominal pain.

Hyperglycemia and new-onset diabetes are frequent and need monitoring. Also slow heart rate, QT prolongation, liver enzyme elevations and adrenal insufficiency.

Who Uses Pasireotide

Adults with Cushing's disease or acromegaly not controlled by other treatment.